MiNK offers high-upside, high-risk exposure to off-the-shelf iNKT cell therapy, where clinical validation could unlock major value but weak liquidity and binary trial risk dominate the investment case.
Overview
MiNK Therapeutics is a pre-revenue clinical-stage biotech developing allogeneic invariant natural killer T cell therapies for oncology, acute lung injury, critical care, and immune disorders. Its lead product, agenT-797, is an off-the-shelf native iNKT therapy positioned as a faster, less toxic alternative to autologous CAR-T approaches. The company has promising early clinical data, differentiated biology, and scalable manufacturing, but no commercial revenue, heavy dependence on trial success, limited cash, and significant dilution risk.